NEW YORK, June 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Aetna Inc (NYSE: AET), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Align Technology, Inc. (NASDAQ: ALGN), Hospira, Inc. (NYSE: HSP) and Omnicare, Inc. (NYSE: OCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3297-100free.

-- Aetna Inc Analyst Notes On May 30, 2014, Aetna Inc (Aetna) announced that its Board of Directors has declared a quarterly cash dividend of $0.225 per share on the Company's common stock, payable on July 25, 2014, to shareholders of record at the close of business as on July 10, 2014. Aetna stated that the declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change. The full analyst notes on Aetna are available to download free of charge at:

http://www.analystsreview.com/Jun-16-2014/AET/report.pdf

-- Salix Pharmaceuticals, Ltd. Analyst Notes On May 28, 2014, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals) announced that it will present at the following conferences in the month of June: the Wells Fargo Securities Healthcare Conference on Wednesday, June 18, 2014, at 1:50 p.m. in Boston, Massachusetts; and at the JMP Health Care Conference on Wednesday, June 25, 2014, at 9:00 a.m., in New York City, New York. Salix Pharmaceuticals informed that live audio webcasts and a replay of the presentations can be accessed through its website. The full analyst notes on Salix Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-16-2014/SLXP/report.pdf

-- Align Technology, Inc. Analyst Notes On May 30, 2014, Align Technology, Inc. (Align Technology) announced a share repurchase plan through which the Company will repurchase up to $30 million of its common stock. The repurchase plan is in addition to, and will become effective upon, the completion of the Company's previously announced $70 million accelerated stock repurchase plan. Align Technology stated that these two share repurchase plans were authorized as a part of the Company's three-year $300 million share repurchase program announced on April 23, 2014. The full analyst notes on Align Technology are available to download free of charge at:

http://www.analystsreview.com/Jun-16-2014/ALGN/report.pdf

-- Hospira, Inc. Analyst Notes On May 30, 2014, Hospira, Inc. (Hospira) issued a press release through which it commended Delaware Governor Jack Markell for signing the Senate Substitute 1 for Senate Bill 118, a law which creates a pathway for the substitution of interchangeable biologic drugs and paves the way for patient access to cost savings from biosimilar products. According to the Company, when biosimilars become available in the US in the coming years, clinicians will be able to provide their patients greater access to effective and cheaper biologic drugs. According to a report quoted by the Company, the introduction of biosimilars can help the US save up to $250 billion over ten years. The full analyst notes on Hospira are available to download free of charge at:

http://www.analystsreview.com/Jun-16-2014/HSP/report.pdf

-- Omnicare, Inc. Analyst Notes On May 27, 2014, Omnicare, Inc. (Omnicare) announced that its Board of Directors has approved a quarterly cash dividend of $0.20 per share on the Company's common stock, payable on June 26, 2014, to all stockholders of record as on June 12, 2014. The full analyst notes on Omnicare are available to download free of charge at:

http://www.analystsreview.com/Jun-16-2014/OCR/report.pdf

-- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review